Clinical Trials
Below are current clinical trials.
68 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Scottsdale/Phoenix, Ariz.
The purpose of this open-label extension of CDI-001 (subsequently referred to as PRISM 3) is to evaluate the safety and efficacy in reducing recurrence of CDI in adults who had a recurrence within 8 weeks of receiving CP101 or placebo in PRISM 3. Subjects who are experiencing recurrent CDI will undergo screening procedures. Subjects who meet eligibility criteria will be eligible to be enrolled in the extension study and administered CP101. Approximately 70 subjects will receive CP101. The treatment duration will be 1 day. Subjects will be monitored for recurrence of CDI, safety, and tolerability for 24 weeks following receipt of CP101. The primary efficacy and safety endpoints will be evaluated at 8 weeks post treatment, and all subjects will continue to be followed for an additional 16 weeks for safety and recurrence of CDI.
-
Rochester, Minn.
The purpose of this study is to provide the lab with a source of human PBMCs and serum from normal and HIV-1-infected individuals. We wish to analyze cells from HIV-infected and non-HIV infected individuals for levels of various proteins and mRNAs that are relevant to HIV research.
-
Scottsdale/Phoenix, Ariz.
The objective of the treatment program described here is to make benznidazole available in the United States on a compassionate-use basis for treatment of T. cruzi infection—specifically, for patients who have acute or congenital infection, reactivated infection, or chronic infection (without advanced cardiac disease)—and for prophylaxis of infection, when indicated in the setting of proven exposure. Benznidazole will be provided for individual patients who meet the eligibility criteria, on request of the treating physician, after consultation with CDC staff.
-
Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.
The purpose of this study is to determine the safety, toxicity and maximum tolerated dose (MTD) / maximum feasible dose (MFD) of Ad/MG1-E6E7, and sequential treatment with atezolizumab in patients with HPV associated cancers.
-
Rochester, Minn.
The purpose of this study is to better understand the role of HIV and/or HCV infection on the immune system and potential ways to eliminate the virus(es).
-
Rochester, Minn.
The purpose of this study is to determine if a special laboratory test performed on a blood sample collected from you (the organ recipient) can accurately predict the risk CMV infection occurring again in the future, after the current disease is cured.
-
Rochester, Minn.
This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B. Hospitalized subjects with influenza A or B that have either a low oxygen level or a high respiratory rate will be eligible for study participation. This study will enroll adults, children and pregnant women.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to determine whether adding clofazimine in a treatment regimen for patients with non-tuberculous mycobacterial (NTM) infections will improve low clinical success rates in NTM infections, its mode of action, and literature reported clinical data in both NTM and multidrug-resistant tuberculosis.
-
Rochester, Minn.
The purpose of this study is to determine the percentage of patients at moderate risk for infective endocarditis (IE) who are receiving antibiotic prophylaxis post-2007 in Olmsted County, Minnesota.
-
Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.
Staphylococcus aureus is responsible for at least 20% of the healthcare associated blood stream infections in the United States. One of the most worrisome complications of S. aureus bacteremia (SAB) is infective endocarditis (IE).Our goal from this project is to prospectively validate the Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT) scoring system and to assess the potential novel risk factors to optimize the PREDICT scoring system prior to formal implementation in clinical practice.